It is with great honor that we remember Robert (Bob) Benson, the inspiration for our Foundation, who died last May 17th from cancer. Bob, who had Guillain Barré Syndrome in 1979, founded the organization with his wife, Estelle.
At his family's request, contributions in his memory can be made to The Robert and Estelle Benson Fellowship in Neuromuscular Neurology, c/o GBS/CIDP Foundation International, 104 1/2 Forrest Ave., Narberth, PA 19072. Please call 610-667-0131.

>> Centers of Excellence

Expert diagnosis & management of inflammatory neuropathies is critical to our patients. This is what our medical advisory board members had in mind when setting up the new Centers of Excellence program. We now have 12 healthcare facilities providing exactly that. More >>

One in 100,000

GBS & CIDP patients share their stories.

GBS/CIDP Foundation International: Our Commitment

The Foundation began over 30 years ago as a support group for patients & families impacted by Guillain‐Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) or any of the variants that exist. Since then, our commitment has been to provide support to those affected by these disorders so that every patient obtains an early diagnosis, proper treatment & the opportunity for a full recovery. More >>

Topics of Interest

Upcoming Special Events

Be sure to register for our 12th International Symposium, taking place from October 25-28 in Fort Worth, Texas. Click here for information on the CME being held on Saturday, October 27 in conjunction with the 12th International Symposium.

People With Rare Diseases Face a Host of Unique Challenges

Dennis Jackman, Senior Vice President of CSL Behring, has written an informative article published in the BIOtechNOW editor on the challenges faced by people with rare diseases, such as GBS and CIDP. He discusses ways to overcome these barriers and methods to improve access to care for patients diagnosed with rare diseases. Click on the above link for full access to the article's contents.

New Treatment for MMN Patients

Baxter International Inc. announces that the U.S. Food and Drug Administration has approved the first immunoglobulin treatment for Multifocal Motor Neuropathy patients in the United States. Click here to learn more.

All content © 2011 GBS/CIDP Foundation International. Use of this Web site constitutes acceptance of our Terms of Use and Privacy Policy Mailing Address: The Holly Building - 104 1/2 Forrest Avenue - Narberth, PA 19072 | Phone: 610-667-0131

All content © 2012 GBS/CIDP Foundation International. Use of this Web site constitutes acceptance of our Terms of Use and Privacy Policy Mailing Address: The Holly Building - 104 1/2 Forrest Avenue - Narberth, PA 19072 | Phone: 610-667-0131